Jefferies analyst Amy Li downgraded Ironwood (IRWD) to Hold from Buy with a price target of 70c, down from $8, after the FDA said the company will likely need another confirmatory Phase 3 trial for apraglutide. The firm cites the regulatory setback for the downgrade and wants more clarity on the path forward before recommending the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRWD:
- Hold Rating on Ironwood Pharma Amid FDA Trial Requirements and Strategic Uncertainties
- Ironwood downgraded to Equal Weight from Overweight at Wells Fargo
- Wells downgrades Ironwood to Equal Weight on ‘major setback’
- Ironwood price target lowered to $1 from $3 at Leerink
- Citizens JMP downgrades Ironwood on delayed apraglutide launch
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue